296 related articles for article (PubMed ID: 35732349)
1. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
[TBL] [Abstract][Full Text] [Related]
2. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
[TBL] [Abstract][Full Text] [Related]
3. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
[TBL] [Abstract][Full Text] [Related]
4. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.
Sei S; Ahadova A; Keskin DB; Bohaumilitzky L; Gebert J; von Knebel Doeberitz M; Lipkin SM; Kloor M
Front Oncol; 2023; 13():1147590. PubMed ID: 37035178
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
7. The Immune Biology of Microsatellite-Unstable Cancer.
Kloor M; von Knebel Doeberitz M
Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
[TBL] [Abstract][Full Text] [Related]
8. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N
Front Immunol; 2021; 12():757804. PubMed ID: 34630437
[TBL] [Abstract][Full Text] [Related]
9. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
[TBL] [Abstract][Full Text] [Related]
10. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
12. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
13. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
Bolivar AM; Duzagac F; Sinha KM; Vilar E
Mol Aspects Med; 2023 Oct; 93():101204. PubMed ID: 37478804
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
[TBL] [Abstract][Full Text] [Related]
15. Towards a vaccine to prevent cancer in Lynch syndrome patients.
von Knebel Doeberitz M; Kloor M
Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.
Clendenning M; Huang A; Jayasekara H; Lorans M; Preston S; O'Callaghan N; Pope BJ; Macrae FA; Winship IM; Milne RL; Giles GG; English DR; Hopper JL; Win AK; Jenkins MA; Southey MC; Rosty C; Buchanan DD;
Fam Cancer; 2018 Jan; 17(1):91-100. PubMed ID: 28616688
[TBL] [Abstract][Full Text] [Related]
17. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
18. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
20. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
